Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Nov 15;208(10):1140-1141.
doi: 10.1164/rccm.202307-1268LE.

Icenticaftor, a Novel Treatment for Chronic Obstructive Pulmonary Disease, Needs Further Verification of Its Effectiveness

Qiming Gan  1 , Kai Yang  1 , Yanjuan Wu  1 , Jingcun Wang  1 , Haojie Zhang  1 , Nuofu Zhang  1 , Kang Wu  1
Affiliations
Comment

Icenticaftor, a Novel Treatment for Chronic Obstructive Pulmonary Disease, Needs Further Verification of Its Effectiveness

Qiming Gan et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply to Gan et al.
    Martinez FJ. Martinez FJ. Am J Respir Crit Care Med. 2023 Nov 15;208(10):1141-1142. doi: 10.1164/rccm.202309-1653LE. Am J Respir Crit Care Med. 2023. PMID: 37748176 Free PMC article. No abstract available.

Comment on

  • Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
    Martinez FJ, Criner GJ, Gessner C, Jandl M, Scherbovsky F, Shinkai M, Siler TM, Vogelmeier CF, Voves R, Wedzicha JA, Bartels C, Bottoli I, Byiers S, Cardenas P, Eckert JH, Gutzwiller FS, Knorr B, Kothari M, Parlikar R, Tanase AM, Franssen FME. Martinez FJ, et al. Am J Respir Crit Care Med. 2023 Aug 15;208(4):417-427. doi: 10.1164/rccm.202303-0458OC. Am J Respir Crit Care Med. 2023. PMID: 37411039 Free PMC article. Clinical Trial.

References

    1. Martinez FJ, Criner GJ, Gessner C, Jandl M, Scherbovsky F, Shinkai M, et al. Icenticaftor, a CFTR potentiator, in COPD: a multicenter, parallel-group, double-blind clinical trial. Am J Respir Crit Care Med . 2023;208:417–427. - PMC - PubMed
    1. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. VX08-770-102 Study Group A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med . 2011;365:1663–1672. - PMC - PubMed
    1. Dransfield M, Rowe S, Vogelmeier CF, Wedzicha J, Criner GJ, Han MK, et al. Cystic fibrosis transmembrane conductance regulator: roles in chronic obstructive pulmonary disease. Am J Respir Crit Care Med . 2022;205:631–640. - PubMed
    1. Fernandez Fernandez E, De Santi C, De Rose V, Greene CM. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease. Expert Rev Respir Med . 2018;12:483–492. - PubMed
    1. Diaz AA, Orejas JL, Grumley S, Nath HP, Wang W, Dolliver WR, et al. Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease. JAMA . 2023;329:1832–1839. - PMC - PubMed

MeSH terms